Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) to Collaborate with Boehringer Ingelheim(BI) for Neuropsychiatric Disorders
Shots
- VCNDD and BI enters into two agreement for the development and commercialization of two small molecules targeting GPCRs for neuropsychiatric disorders
- The focus of the agreement is to develop and expand therapies for neurological conditions including maladaptive brain circuitry
- GPCRs(G-protein coupled receptors) are protein involved in regulation of brain circuit functions targeting schizophrenia- further helps in activatingsignal transduction pathways
Ref: VCNDD | Image: The Pharma Letter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
